CO6270301A2 - Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usos - Google Patents

Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usos

Info

Publication number
CO6270301A2
CO6270301A2 CO10054082A CO10054082A CO6270301A2 CO 6270301 A2 CO6270301 A2 CO 6270301A2 CO 10054082 A CO10054082 A CO 10054082A CO 10054082 A CO10054082 A CO 10054082A CO 6270301 A2 CO6270301 A2 CO 6270301A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical compositions
compositions containing
bradiquinine
antagonists
hialuronic acid
Prior art date
Application number
CO10054082A
Other languages
English (en)
Inventor
Carlos Alberto Maggi
Sandro Giuliani
Laura Quartara
Original Assignee
Luso Farmaco Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luso Farmaco Inst filed Critical Luso Farmaco Inst
Publication of CO6270301A2 publication Critical patent/CO6270301A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se describen las composiciones farmacéuticas que contienen, como ingredientes activos, una mezcla de un polimero de acido hialuronico con un antagonista del receptor de bradiquinina B2. Se ha comprobado que dichas composiciones son especialmente efectivas en el tratamiento de enfermedades articulares degenerativas tales como osteoartritis usando inyecciones intraarticulares.
CO10054082A 2007-11-23 2010-05-06 Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usos CO6270301A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002225A ITMI20072225A1 (it) 2007-11-23 2007-11-23 "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso"

Publications (1)

Publication Number Publication Date
CO6270301A2 true CO6270301A2 (es) 2011-04-20

Family

ID=40314753

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10054082A CO6270301A2 (es) 2007-11-23 2010-05-06 Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usos

Country Status (41)

Country Link
US (1) US9101627B2 (es)
EP (1) EP2222275B1 (es)
JP (1) JP5383695B2 (es)
KR (1) KR101585868B1 (es)
CN (1) CN101868225B (es)
AP (1) AP2628A (es)
AR (1) AR069407A1 (es)
AT (1) ATE529096T1 (es)
AU (1) AU2008328311B2 (es)
BR (1) BRPI0820402A2 (es)
CA (1) CA2706398C (es)
CL (1) CL2008003475A1 (es)
CO (1) CO6270301A2 (es)
CR (1) CR11457A (es)
CY (1) CY1112134T1 (es)
DK (1) DK2222275T3 (es)
EA (1) EA017626B1 (es)
EC (1) ECSP10010153A (es)
ES (1) ES2374861T3 (es)
GE (1) GEP20125602B (es)
HK (1) HK1149714A1 (es)
HN (1) HN2010001037A (es)
HR (1) HRP20110904T1 (es)
IL (1) IL205860A (es)
IT (1) ITMI20072225A1 (es)
MA (1) MA31913B1 (es)
MX (1) MX2010005484A (es)
MY (1) MY148685A (es)
NI (1) NI201000087A (es)
NZ (1) NZ585514A (es)
PA (1) PA8804801A1 (es)
PE (1) PE20091422A1 (es)
PL (1) PL2222275T3 (es)
PT (1) PT2222275E (es)
RS (1) RS52045B (es)
SI (1) SI2222275T1 (es)
TN (1) TN2010000215A1 (es)
TW (1) TWI448292B (es)
UA (1) UA97867C2 (es)
WO (1) WO2009065507A2 (es)
ZA (1) ZA201003586B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO131947A2 (ro) * 2014-05-30 2017-06-30 Nataliia Mykolaivna Derkach Soluţie stabilizată bazată pe substanţe active, şi metodă de preparare a soluţiei stabilizate de substanţe active
EP3238728B1 (en) 2014-12-26 2020-09-02 Seikagaku Corporation Agent comprising hyaluronic acid having an aminoalkyl cinnamate covalently bonded thereto for improving subjective symptoms in eyes
US11401303B2 (en) * 2020-06-15 2022-08-02 Taian City Qihang Biotechnology Co. Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635489B2 (en) * 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
ITMI20021247A1 (it) * 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"

Also Published As

Publication number Publication date
ZA201003586B (en) 2011-08-31
NI201000087A (es) 2011-07-18
WO2009065507A2 (en) 2009-05-28
HN2010001037A (es) 2012-12-10
GEP20125602B (en) 2012-08-10
EP2222275A2 (en) 2010-09-01
CR11457A (es) 2010-11-05
US9101627B2 (en) 2015-08-11
EP2222275B1 (en) 2011-10-19
CN101868225B (zh) 2013-06-12
ITMI20072225A1 (it) 2009-05-24
CY1112134T1 (el) 2015-11-04
SI2222275T1 (sl) 2012-01-31
JP2011504473A (ja) 2011-02-10
BRPI0820402A2 (pt) 2015-05-19
AP2628A (en) 2013-03-26
PA8804801A1 (es) 2009-06-23
EA017626B1 (ru) 2013-01-30
PT2222275E (pt) 2012-01-16
AU2008328311A1 (en) 2009-05-28
NZ585514A (en) 2012-01-12
US20100292156A1 (en) 2010-11-18
AP2010005265A0 (en) 2010-06-30
DK2222275T3 (da) 2012-01-02
EA201000678A1 (ru) 2010-12-30
HK1149714A1 (en) 2011-10-14
PE20091422A1 (es) 2009-10-17
ECSP10010153A (es) 2010-06-29
TW200927151A (en) 2009-07-01
ATE529096T1 (de) 2011-11-15
RS52045B (en) 2012-04-30
AR069407A1 (es) 2010-01-20
TWI448292B (zh) 2014-08-11
MA31913B1 (fr) 2010-12-01
HRP20110904T1 (hr) 2011-12-31
WO2009065507A3 (en) 2009-09-03
IL205860A0 (en) 2010-11-30
MY148685A (en) 2013-05-31
KR20100096106A (ko) 2010-09-01
CL2008003475A1 (es) 2009-03-27
TN2010000215A1 (en) 2011-11-11
JP5383695B2 (ja) 2014-01-08
MX2010005484A (es) 2010-06-07
PL2222275T3 (pl) 2012-03-30
ES2374861T3 (es) 2012-02-22
KR101585868B1 (ko) 2016-01-22
UA97867C2 (ru) 2012-03-26
CN101868225A (zh) 2010-10-20
CA2706398A1 (en) 2009-05-28
AU2008328311B2 (en) 2013-02-28
CA2706398C (en) 2016-07-05
IL205860A (en) 2013-01-31

Similar Documents

Publication Publication Date Title
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
PH12015501738A1 (en) Androgen receptor modulators and uses thereof
CL2011000668A1 (es) Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
IN2012DN02177A (es)
IN2012DN00754A (es)
BR112014012789A2 (pt) agentes terapêuticos compreendendo sequências de aminoácidos de insulina
MY193728A (en) Muscarinic receptor agonists
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
MX2019011545A (es) Composiciones celulares y de andamio inyectables.
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
CO6270301A2 (es) Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usos
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.
CL2007001857A1 (es) Compuestos derivados del acido fenil-acetico, inhibidores de cox-2; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, osteoartritis, dolor, entre otras.
ECSP11010752A (es) Composiciones farmacéuticas basadas en antagonistas del receptor de quinina b2 y corticosteroides
CL2015000053A1 (es) Composicion líquida oral pediátrica que comprende nepadutant y tpgs; proceso para prepararla; util en el tratamiento de enfermedades intestinales.
UY32679A (es) Antagonistas policíclicos de receptores de ácido lisofosfatidico
EA200900172A1 (ru) Фармацевтическая композиция для контрацепции

Legal Events

Date Code Title Description
FG Application granted